⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2292307 | 0.96 | — | — | |
| SCHEMBL17188582 | 0.81 | — | — | |
| SCHEMBL44897 | 0.78 | — | — | |
| SCHEMBL148914 | 0.78 | — | — | |
| Urea SCHEMBL28413412 | 0.77 | LMNA (0.46) | — | |
| SCHEMBL14952764 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL4462514 | 0.74 | — | — | |
| SCHEMBL28662436 | 0.74 | — | — | |
| SCHEMBL29165409 | 0.74 | — | — | |
| SCHEMBL29131062 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889676-B2 | 3-ureidoisoquinolin-8-yl derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | claimed |
| US-20140038961-A1 | 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-02-06 | — | — | US | claimed |
| EP-2691373-A1 | 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2014-02-05 | — | — | EP | claimed |
| WO-2012131588-A1 | 3-UREIDOISOQUINOLIN-8-YL DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-10-04 | — | — | WO | claimed |
| US-7214738-B2 | Golf ball layers formed of polyurethane-based and polyurea-based compositions incorporating block copolymers | ACUSHNET COMPANY (US) | 2007-05-08 | — | — | US | claimed |
| US-20050009642-A1 | Golf ball layers formed of polyurethane-based and polyurea-based compositions incorporating block copolymers | JPMORGAN CHASE BANK, N.A., AS SUCCESSOR ADMINISTRATIVE AGENT | 2005-01-13 | — | — | US | claimed |
| WO-2025085848-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2025054132-A1 | ANTIBACTERIAL COMPOUNDS | ARREPATH, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| CN-110172714-A | A kind of combined additive and preparation method thereof for the production of diamond cut scroll saw | 武汉天立表面技术有限公司 | 2019-08-27 | — | — | CN | disclosed |
| CN-106661144-A | Ultrafiltration of polyisoolefin copolymers | 阿朗新科新加坡私人有限公司 | 2017-05-10 | — | — | CN | disclosed |
| EP-3049424-A1 | ORGANOMETALLIC COMPOUNDS FOR USE AS ANTHELMINTICS | Universität Zürich (CH) | 2016-08-03 | — | — | EP | disclosed |
| US-20160207951-A1 | ORGANOMETALLIC COMPOUNDS FOR USE AS ANTHELMINTICS | Universität Zürich (CH) | 2016-07-21 | — | — | US | disclosed |
| US-20160207951-A1 | ORGANOMETALLIC COMPOUNDS FOR USE AS ANTHELMINTICS | Universität Zürich (CH) | 2016-07-21 | — | — | US | disclosed |
| WO-2003074529-A2 | iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS | PFIZER INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003057204-A2 | MODULATION OF IAMT (PIMT OR PCMT) IN IMMUNE SYSTEM | NORDIC BIOSCIENCE A/S (DK) | 2003-07-17 | — | — | WO | disclosed |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| US-5807875-A | OBESITY THERAPY | DR. KARL THOMAE GMBH (DE) | 1998-09-15 | — | — | US | disclosed |
| US-5780501-A | ADMINISTERING TO A MAMMAL | NOVARTIS CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| US-5780500-A | Anti-neurodegeneratively active 10-aminoaliphatyl-dibenzi b,f! oxepines | NOVARTIS CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| US-5616620-A | HYPOTENSIVE AGENTS | KARL THOMAE GMBH (DE) | 1997-04-01 | — | — | US | disclosed |